Retraction: Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice (Cancer Prevention Research (2013) 6 (886-897) DOI: 10.1158/1940-6207.CAPR-13-0140);Dietary polyphenols suppress elevated levels of proin flammatory mediators and aromatase in the mammary gland of obese mice

Cancer Prevention Research

Volumn 6, Issue 9, 2013, Pages 886-897

  Subbaramaiah, Kotha ^a   Sue, Erika ^a   Bhardwaj, Priya ^a   Du, Baoheng ^a   Hudis, Clifford A ^a,b   Giri, Dilip ^b   Kopelovich, Levy ^c   Zhou, Xi Kathy ^a   Dannenberg, Andrew J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CURCUMIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; OLIVE OIL; PLANT EXTRACT; POLYADENYLATED RNA; POLYPHENOL; PROTEIN KINASE B; RESVERATROL; RNA; SATURATED FATTY ACID; STEARIC ACID; TUMOR NECROSIS FACTOR ALPHA; TURMERIC;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAIKAL SKULLCAP; BASIL; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; COPTIS CHINENSIS; DIETARY INTAKE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GINGER; HERB; HU ZHANG; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; MACROPHAGE; MAMMARY GLAND; MICROSCOPY; MOUSE; NONHUMAN; OBESITY; OREGANO; PLANT; POSTMENOPAUSE; PRIORITY JOURNAL; PROADIPOCYTE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RISK REDUCTION; ROSEMARY; SIGNAL TRANSDUCTION; TEA; TISSUE CULTURE;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; AROMATASE; BLOTTING, WESTERN; CELLS, CULTURED; DIET; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MAMMARY GLANDS, HUMAN; MICE; MICE, INBRED C57BL; MICE, OBESE; NF-KAPPA B; OBESITY; PHOSPHATIDYLINOSITOL 3-KINASES; POLYPHENOLS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84883829545     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-22-0206     Document Type: Erratum

References (49)

1. Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 2009;150:2537-42.
2. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
4. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2005;14:2009-14. (Pubitemid 41161216)
5. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111:329-42.
6. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 2002;13:325-32. (Pubitemid 34553513)
7. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011;29:25-31.
8. Rose DP, Vona-Davis L. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther 2009;9:1091-101.
9. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-35.
10. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83. (Pubitemid 41196955)
11. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26. (Pubitemid 37069552)
12. Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007;66:440-6. (Pubitemid 46239306)
13. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol 2010;28:4058-65.
14. Subbaramaiah K, HoweLR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with infl ammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4:329-46.
15. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021-9.
16. Nicklas BJ, Rogus EM, Colman EG, Goldberg AP. Visceral adiposity, increased adipocyte lipolysis, and metabolic dysfunction in obese postmenopausal women. Am J Physiol 1996;270:E72-8.
17. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A subpopulation of macrophages in filtrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007;282:35279-92. (Pubitemid 350232441)
18. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009;486:95-102.
19. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270:24995-5000.
20. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008;149:3549-58. (Pubitemid 351919581)
21. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr 2003;133:3262S-7S. (Pubitemid 37222254)
22. Frojdo S, Cozzone D, Vidal H, Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J 2007;406:511-8. (Pubitemid 47425457)
23. Busch F, Mobasheri A, Shayan P, Lueders C, Stahlmann R, Shakibaei M. Resveratrol modulates interleukin-1β-induced phosphatidylinositol 3-kinase and nuclear factor κB signaling pathways in human tenocytes. J Biol Chem 2012;287:38050-63.
24. Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, et al. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-kB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IkB kinase complex signaling axis in adenoid cystic carcinoma. Mol Pharmacol 2011;79:106-18.
25. Lin ML, Lu YC, Chen HY, Lee CC, Chung JG, Chen SS. Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1α-induced invasion of human esophageal carcinoma cells. Mol Carcinog 2012 Nov 28. [Epub ahead of print]
26. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 2006;5:1227-38. (Pubitemid 43881315)
27. Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, et al. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun 2011;406:194-9.
28. Sandur SK, Ahn KS, Ichikawa H, Sethi G, Shishodia S, Newman RA, et al. Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-κB activation and NF-κB-regulated gene products. Nutr Cancer 2007;57:78-87. (Pubitemid 46871572)
29. Huang EC, McEntee MF, Whelan J. Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer. Nutr Cancer 2012;64:749-60.
30. Mohebati A, Guttenplan JB, Kochhar A, Zhao ZL, Kosinska W, Subbaramaiah K, et al. Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. Cancer Prev Res 2012;5:593-602.
31. Yang P, Sun Z, Chan D, Cartwright CA, Vijjeswarapu M, Ding J, et al. Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[α]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis 2008;29:2182-9.
32. Huang EC, Chen G, Baek SJ, McEntee MF, Collier JJ, Minkin S, et al. Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer. Nutr Cancer 2011;63:1287- 96.
33. Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, Benson MC, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 2009;7:43-51.
34. Yan J, Xie B, Capodice JL, Katz AE. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Prostate 2012;72:244-52.
35. Bhardwaj P, Du B, Zhou XK, Sue E, Harbus MD, Falcone DJ, et al. Caloric restriction reverses obesity-induced mammary gland inflammation in mice. Cancer Prev Res 2013;6:282-9.
36. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
37. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008;283:3433-44.
38. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008;22:1490-500. (Pubitemid 351793083)
39. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
40. Davidson NE, Kensler TW. "MAPping" the course of chemoprevention in breast cancer. N Engl J Med 2011;364:2463-4.
41. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
42. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-46.
43. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk b. Science 2001;293:1673-7. (Pubitemid 32807849)
44. Kim JK, KimYJ, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46. (Pubitemid 32730790)
45. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, et al. Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor IκB kinase activity. J Immunol 1999;163:3474-83. (Pubitemid 29431852)
46. Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-κB activation by inhibiting IκB kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001;60:528-33. (Pubitemid 32781560)
47. Park W, Amin AR, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev Res 2013;5:387-400.
48. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks L, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging and lung metastases in patients with breast cancer. Cancer Prev Res 2013;5:428-36.
49. Reilly SM, Chiang SH, Decker SJ, Chang L,UhmM, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med 2013; 19:313-21.